Cytek BiosciencesCTKB +0.11%71 PB Ratio is 1.76 as of Jun. 27, 2026, which is 21% below its 10-year median of 2.22. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.82 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Cytek Biosciences ranks better than 57.11% on this metric.
The historical rank and industry rank for Cytek Biosciences's PB Ratio or its related term are showing as below:
CTKB'
s PB Ratio Range Over the Past 10 Years
Min: 0.81 Med: 2.22 Max: 8.2
Current: 1.76
During the past 7 years, Cytek Biosciences's highest PB Ratio was 8.20. The lowest was 0.81. And the median was 2.22.
CTKB's PB Ratio is ranked better than 57.11% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs CTKB: 1.76
During the past 12 months, Cytek Biosciences's average Book Value Per Share Growth Rate was -14.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -5.40% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Cytek Biosciences was 0.40% per year. The lowest was -5.40% per year. And the median was -2.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cytek Biosciences PB Ratio Related Terms
Cytek Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cytek Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cytek Biosciences (CTKB) has a PB Ratio of 1.76 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cytek Biosciences and its competitors. This is 21% below median its historical median of 2.22. Over the past decade, Cytek Biosciences' PB Ratio has ranged from 0.81 to 8.20. According to the industry distribution chart, Cytek Biosciences ranks #338 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 42.9%.
Is Cytek Biosciences' PB Ratio too high?
Cytek Biosciences' current PB Ratio of 1.76 is 21% below median its 10-year median of 2.22. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 8.20. The Medical Devices & Instruments industry median PB Ratio is 2.02. Cytek Biosciences' value of 1.76 is 12.9% below this industry median. Based on the distribution chart, Cytek Biosciences ranks #338 out of 788 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' PB Ratio compare to BBNX and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #338 out of 788 companies for PB Ratio. This puts Cytek Biosciences in the upper half of its industry. The industry median PB Ratio is 2.02. Cytek Biosciences' value of 1.76 is 12.9% below this benchmark. Historically, Cytek Biosciences' own PB Ratio has ranged from 0.81 to 8.20 over the past decade. While the company's 10-year median is 2.22 vs. the industry median of 2.02, Cytek Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current PB Ratio of 1.76 is 12.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current PB Ratio is 1.76, which is 21% below median its own 10-year median of 2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.82, compared to a current price of $4.46 — trading 23.4% below its estimated fair value. The current PB Ratio is 1.76, which is 21% below median its 10-year median of 2.22 and 12.9% below the Medical Devices & Instruments industry median of 2.02. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current PB Ratio is 1.76 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.46 is trading 23.4% below its estimated GF Value™ of $5.82.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
PB Ratio: 1.76 (21% below median its 10-year median of 2.22)
GF Value™: $5.82 vs. price of $4.46 (23.4% below fair value)
Industry Position: 12.9% below the Medical Devices & Instruments median (#338 of 788)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
